By Andrea Zobel
Published in: IVT Jr GXP Compliance Vol. 24, Issue 3
Published on: May 29, 2020
Introduction: IMPs (Investigational Medicinal Products) are not mentioned in current GDP guidance e.g. the EU GDP guidance or USP 1079 in the USA, but GMP and GCP regulations and principles request the same or even higher level of traceability and quality for IMP distribution and storage than for commercial medicinal products. At each moment in the clinical trial, sponsor, monitor and investigator must know the location, status, distribution history and usage of each individual IMP package. The whole supply chain must be documented, and related documentation is part of clinical trial files.